Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.

BACKGROUND: In most cases, T790M EGFR-positive NSCLC patients receiving osimertinib developed "non-drugable" progression, as the patients with common EGFR-sensitizing mutations were treated with first-line osimertinib. In both settings, chemotherapy represents the standard treatment and local ablative treatments (LATs) are potential useful options in the case of oligo-progression. METHODS: We conducted a study on "post-progression" (pp) outcomes of T790M EGFR-positive NSCLC patients treated with osimertinib, according to the therapeutic strategy applied: osimertinib beyond progression (± LATs), "switched therapies" or best supportive care only (BSC). RESULTS: 144 consecutive patients were evaluated: 53 (36.8%) did not received post-progression treatments (BSC), while 91 (63.2%) patients received at least 1 subsequent treatment; 50 patients (54.9%) received osimertinib beyond disease progression [19 (20.9%) of them with adjunctive LATs] and 41 (45.1%) a switched therapy. Median ppPFS (progression-free survival) and median ppOS (overall survival) of patients who received osimertinib beyond progression vs. switched therapies were 6.4 months vs. 4.7 months, respectively [HR 0.57 (95% CI 0.35-0.92), p = 0.0239] and 11.3 months vs 7.8 months, respectively [HR 0.57 (95% CI 0.33-0.98), p = 0.0446]. Among patients who received osimertinib beyond progression with and without LATs median ppPFS was 6.4 months and 5.7 months, respectively [HR 0.90 (95% CI 0.68-1.18), p = 0.4560], while median ppOS was 20.2 months and 9.9 months, respectively [HR 0.73 (95% CI 0.52-1.03), p = 0.0748]. At the univariate analysis, the only factor significantly related to the ppPFS was the therapeutic strategy in favor of osimertinib beyond progression (± LATs). Moreover, the only variable which was significantly related to ppOS at the multivariate analysis was osimertinib beyond progression (± LATs). CONCLUSION: Our study confirmed that in clinical practice, in case of "non-druggable" disease progression, maintaining osimertinib beyond progression (with adjunctive LATs) is an effective option.

Anatomical evaluation of some morphological abnormalities related to periodontal diseases

The presence of some dental abnormalities as a predisposal factor to installation of localized periodontal alterations. The present study was to evaluate the frequency of development abnormalities present on a sample of molars that may predispose to occurrence and progression of periodontal disease. Two hundred and seventy seven molars (141 maxillary and 136 mandibular molars) were selected for this study. The evaluations were performed by two examiners together who was trained and calibrated for the study. All measurements were made by direct visualization with a magnifying glass. The following clinical parameters were measured: Enamel cervical projections; Root trunk: in the three different extensions (<3 mm, >3 mm and <6 mm, >6 mm); Enamel pearls: presence (1) or absence (0). The anatomic observations were made on four surfaces of the tooth: mesial, distal, vestibular and palatal/lingual. Descriptive statistics and percentage distribution were performed. A total of 130 molars showed at least some degree of enamel cervical projection and the most frequent score was the degree 1, according to Masters and Hoskins classification. Fifteen teeth presented enamel pearls and the root trunk was more evident on the group with variation from 3 to 6 mm of extension, observed in 64 teeth. It can be concluded that the presence of development abnormalities is a frequent finding in molars and it has to be taken into consideration during periodontal examination and therapy.